318 related articles for article (PubMed ID: 7482575)
1. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
2. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
Kontoghiorghes GJ
Arch Toxicol Suppl; 1996; 18():202-14. PubMed ID: 8678796
[No Abstract] [Full Text] [Related]
3. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Kontoghiorghes GJ
Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
[TBL] [Abstract][Full Text] [Related]
4. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
[TBL] [Abstract][Full Text] [Related]
5. Chelation of aluminium by combining DFO and L1 in rats.
Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
[TBL] [Abstract][Full Text] [Related]
6. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
8. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
Fernández-Martín JL; Menéndez-Fraga P; Canteros MA; Díaz-López JB; Cannata-Andía JB
Clin Chim Acta; 1994 Oct; 230(2):137-45. PubMed ID: 7834865
[TBL] [Abstract][Full Text] [Related]
9. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
[TBL] [Abstract][Full Text] [Related]
10. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
12. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro.
Cunningham JM; al-Refaie FN; Hunter AE; Sheppard LN; Hoffbrand AV
Eur J Haematol; 1994 Mar; 52(3):176-9. PubMed ID: 8168597
[TBL] [Abstract][Full Text] [Related]
13. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
Naves Díaz ML; Elorriaga R; Canteros A; Cannata Andía JB
Nephrol Dial Transplant; 1998; 13 Suppl 3():23-8. PubMed ID: 9568816
[TBL] [Abstract][Full Text] [Related]
14. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Sheppard LN; Kontoghiorghes GJ
Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
16. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Chua AC; Ingram HA; Raymond KN; Baker E
Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
[TBL] [Abstract][Full Text] [Related]
17. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Barr J; Baillod RA
Arzneimittelforschung; 1994 Apr; 44(4):522-6. PubMed ID: 8011008
[TBL] [Abstract][Full Text] [Related]
18. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
[TBL] [Abstract][Full Text] [Related]
19. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
20. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
Jeremy JY; Kontoghiorghes GJ; Hoffbrand AV; Dandona P
Biochem J; 1988 Aug; 254(1):239-44. PubMed ID: 3140797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
